Shots:
- The P-IIb study will evaluate three dose levels of ION449 (once a month, SC) vs PBO and will enroll ~108 patients aged 18-75yrs., who have LDL-C levels b/w 70-190 mg/dL and are receiving moderate/ high-intensity statin therapy
- The P-I study results demonstrated dose-dependent mean reductions in circulating plasma PCSK9 and LDL-C levels of >90% and ~70% respectively
- AstraZeneca granted $20M as a milestone to Ionis for the initiation of the P-II study. ION449 is antisense therapy designed to reduce blood cholesterol levels in patients with dyslipidemia by targeting PCSK9
Click here to read full press release/ article | Ref: PRNewswire | Image: The New York Times
The post AstraZeneca Initiates P-IIb Study of ION449 (AZD8233) to Lower LDL-cholesterol first appeared on PharmaShots.
